L. Couronné, E. Lippert, J. Andrieux, O. Kosmider, I. Radford-Weiss, D. Penther, et al., “Analyses of TET2 Mutations in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemias,” Leukemia, Vol. 24, No. 1, 2009, pp. 201-203.

has been cited by the following article:

• TITLE: TET2 Mutations in Ph-Negative-Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings

  AUTHORS: Andrea Patriarca, Donatella Colaizzo, Gianluca Tiscia, Raffaele Spadano, Silvia Di Zacomo, Antonio Spadano, Ida Villanova, Maurizio Margaglione, Elvira Grandone, Alfredo Dragani

  KEYWORDS: MPN; Methylation; TET2; Molecular Biology

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.3 No.3, September 16, 2013

  ABSTRACT: High-throughput DNA sequence analysis was used to screen for TET2 mutations in peripheral blood derived DNA from 97 patients with BCR-ABL-negative-myeloproliferative neoplasms (MPNs). Overall six mutations in the coding region of the gene were identified in 7 patients with an overall mutational frequency of 7.2%. In polycythemia vera patients (n = 25) were identified 2 mutations (8%); in those with essential thrombocythemia (n = 55) 2 mutations (3.6%); in those with unclassifiable MPN (n = 8) 3 mutations (37.5%). No primary myelofibrosis patiens (n = 6) harboured TET2 mutations. Three unreported mutations were identified (p.P177fs, p.C1298del, p.P411del) the first two in patients with unclassifiable MPN, the last in a patient with essential thrombocythemia. On multivariate analysis the diagnosis of an unclassifiable MPN was significantly related to the presence of TET2 mutations (p = 0.02; OR: 2.81; 95% CI 1.11 - 7.06). We conclude that TET2 mutations occur in both JAK2V617F-positive and -negative MPN and are more frequent in MPN-U patients. This could represent the biological link between the different classes of myeloid malignancies.